Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

310
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
310
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

184
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
184
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Imeglimin as a Replacement Therapy for Metformin in Patients With Type 2 Diabetes Mellitus Experiencing Metformin Intolerance: A Retrospective Observational Study.

Cureus·2026
Same author

Osteoporosis and fragility fracture burden in Asia Pacific: Key findings from the APCO-IOF Asia Pacific Regional Audit.

Osteoporosis and sarcopenia·2026
Same author

Benefits Beyond Hypertension Control: Current and Evolving Treatment Strategies for Prevention of Cardiovascular Diseases.

Current hypertension reviews·2026
Same author

Severe Short Stature Secondary to Nutritional Vitamin D Deficiency During COVID-19 Pandemic.

Indian journal of pediatrics·2026
Same author

Regional data, global lessons: what the Asia-Pacific osteoporosis audit teaches the world.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Delayed diagnosis of juvenile hemochromatosis due to missed ferritin testing in a case of hypogonadotropic hypogonadism.

JCEM case reports·2026

Related Experiment Video

Updated: Jul 17, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K

Simplifying Type 2 DM Care with Linagliptin: A Position Paper.

Ambrish Mithal1, Ambady Ramachandran2, Arpandev Bhattacharyya3

  • 1Chairman and Head, Department of Endocrinology and Diabetes, Max Healthcare, Delhi.

The Journal of the Association of Physicians of India
|August 31, 2023
PubMed
Summary

Linagliptin simplifies type 2 diabetes mellitus (T2DM) management with effective glucose control. This dipeptidyl peptidase 4 (DPP-4) inhibitor offers a favorable safety profile and requires no dose adjustment across diverse patient groups.

More Related Videos

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

9.5K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.9K

Related Experiment Videos

Last Updated: Jul 17, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.9K
Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets
10:09

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

9.5K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.9K

Area of Science:

  • Pharmacology
  • Endocrinology
  • Internal Medicine

Background:

  • Type 2 diabetes mellitus (T2DM) presents a growing global health challenge, particularly in India.
  • Effective hyperglycemia management often necessitates complex combination therapies.
  • Recent advancements have introduced novel agents to improve glycemic control in T2DM.

Purpose of the Study:

  • To evaluate the simplicity and clinical utility of linagliptin in T2DM management.
  • To assess the efficacy and safety profile of linagliptin, a selective DPP-4 inhibitor.
  • To provide insights into linagliptin's use in specific patient populations.

Main Methods:

  • Advisory board meetings were convened with 87 key opinion leaders (KOLs) in diabetes care across India.
  • Discussions focused on the practical aspects and perceived simplicity of linagliptin therapy.
  • Literature review and consensus building on clinical data regarding linagliptin's efficacy and safety.

Main Results:

  • Linagliptin, a xanthine-based DPP-4 inhibitor, demonstrates a distinct pharmacological profile.
  • It is associated with a reduced risk of hypoglycemia compared to sulfonylureas and is weight-neutral.
  • No dose modification is required for linagliptin across a wide spectrum of T2DM patients.

Conclusions:

  • Linagliptin offers a simplified approach to T2DM management, balancing efficacy with ease of use.
  • Its favorable profile extends to patients with renal impairment, cardiovascular risk, and heart failure.
  • Linagliptin represents a valuable therapeutic option for broad T2DM patient populations.